

**atorvastatin (Lipitor)**

**(No. 202/05)**

**Pfizer Ltd**

**Product Update**

9 September 2005

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

Atorvastatin calcium (Lipitor<sup>®</sup>) is accepted for restricted use in the NHS in Scotland as an adjunct to diet for the reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides in children aged 10 years and older with primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non-pharmacological measures is inadequate.

It is restricted to initiation by paediatricians or physicians specialising in the management of lipid disorders.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 14 July 2005.*

**Chairman, Scottish Medicines Consortium**